Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04362241
Other study ID # OphthalmicConsultantsOC
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date August 7, 2020
Est. completion date March 2022

Study information

Verified date August 2020
Source Ophthalmic Consultants of the Capital Region
Contact Suzanne Alterman, RN, BSN
Phone 518-274-3123
Email salterman@ophthalmicconsultants.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The complicated schedules for administering topical steroid eye drops combined with forgetfulness and physical difficulties instilling the drops may compromise compliance; which in turn could increase the risk for secondary complications such as PME post-cataract surgery, especially in a high-risk diabetic population. Dextenza, a sustained- release steroid insert, could help preclude adherence difficulties and provide better bioavailability, being as effective as, or more effective than steroid drops in preventing PME. The aim of this study is to assess the incidence of PME in diabetic patients undergoing cataract surgery when comparing the Dextenza insert to topical prednisolone acetate 1% drops.


Description:

This prospective, open-label, single-center, randomized, fellow-eye, investigator-sponsored clinical study seeks to investigate the incidence of PME in diabetic patients with any level of background diabetic retinopathy undergoing cataract surgery treated with a 0.4mg dexamethasone intracanalicular insert when compared to standard of care prednisolone acetate 1% QID/1 week, TID/ 1 week, BID/ 1 week, QD/1 week. Topical NSAIDs will not be used in this study and all patients will receive an intracameral injection of moxifloxacin at the end of the surgical procedure. After screening a patient for inclusion and exclusion criteria, and gaining informed consent, each eye will undergo cataract surgery on separate days. The second eye will be operated on within 60 days of the first eye's surgery. One eye will be randomized to receive the dexamethasone insert using a coin flip. The other eye will be prescribed a prednisolone acetate 0.1% eye drop QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week regimen. The dexamethasone insert will be placed 2-4 days before surgery (Day -4 to Day-2) and those randomized to receive prednisolone acetate will start 2-4 days before surgery. After surgery, each eye will be followed for a period of approximately 60 days, consisting of four post-op follow-up visits (eight total post-op visits per patient). Primary and secondary endpoints will be assessed alongside standard-of-care procedures at all study visits . Adjusting for the enrollment period, the study will last a total of approximately 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 2022
Est. primary completion date February 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Binocular

- >18 years old

- Any level of Background Diabetic Retinopathy

- Cataract surgery candidate in each eye

- Pre-operative OCT and Fluorescein Angiography showing no Macular edema

Exclusion Criteria:

- Participant cannot complete second eye operation within 60 days of the first cataract surgery

- Maintains regular use of systemic or ocular steroids at time of enrollment

- Maintains regular use of systemic or ocular non-steroidal anti-inflammatory drugs at time of enrollment

- Anterior chamber cells present at time of enrollment

- Recent febrile illness that precludes or delays participation for 90 days

- Pregnancy or lactation

- Known allergy to dexamethasone

- Known allergy to prednisolone

- Preexisting retinal disease including uveitis, nondiabetic retinal disease, choroidal disorders, diabetic macular edema.

- Posterior capsule rupture or other intraoperative complication in first eye operated on

- Amblyopia

- Anti-VEGF injections within 6 months prior to surgery day.

- Intraocular steroid injection within 6 months prior to surgery day.

- Intraocular surgeries within 6 months prior to surgery day.

- Laser photocoagulation within 30 days prior to surgery day.

- Any type of eye inflammation

- Any punctum inflammation or dacryocystitis

Study Design


Intervention

Drug:
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Prednisolone Acetate 1% ophthalmic drops

Locations

Country Name City State
United States Ophthalmic Consultants of the Capital Region Troy New York

Sponsors (1)

Lead Sponsor Collaborator
Ophthalmic Consultants of the Capital Region

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 7 on Optical Coherence Tomography at Day 7 by a masked grader. 7 days
Primary To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. Percentage of eyes that developed post-surgical PME in each group measured on optical coherence tomography at Day 30 by a masked grader. 30 days
Primary To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 60 and on optical coherence tomography at Day 60 by a masked grader. 60 days
Secondary Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT) Mean central subfield thickness (CST) at Day 7 post op in each group and comparison between groups. 7days
Secondary Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT) Mean central subfield thickness (CST) at Day 30 post op in each group and comparison between groups. 30 days
Secondary Incidence of central subfield thickness (CST) at Day 60 post op as seen on optical coherence tomography (OCT) Mean central subfield thickness (CST) at Day 60 post op in each group and comparison between groups. 60 days
Secondary To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups. 7 days
Secondary To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups. 30 days
Secondary To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups. 60 days
Secondary To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 7 post op 7 days
Secondary To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 30 post op 30 days
Secondary To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 60 post op 60 days
Secondary Difference patients with absence of anterior chamber (AC) cells at Day 7 post op Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 7 7 days
Secondary Difference patients with absence of anterior chamber (AC) cells at Day 30 post op Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 30 30 days
Secondary Difference patients with absence of anterior chamber (AC) cells at Day 60 post op Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 60 30 days
Secondary Self reported patient experience of comfort Self-reported patient experience of comfort (right eye vs. left eye) at Day 60. 60 days
Secondary Rescue Therapy Percentage of eyes rescued in each group. 60 days
See also
  Status Clinical Trial Phase
Recruiting NCT06066021 - Evaluation of a Health Education Program for Type 2 Diabetes Patients N/A
Recruiting NCT06376240 - The Effect of Pyridoxamine Supplementation on Microvascular Function in Type 2 Diabetes N/A
Completed NCT01506895 - A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema Phase 2
Recruiting NCT04025996 - REWARD: Using the REtina as a Window To Detect Cardiac microvasculAR Dysfunction In Diabetes Mellitus
Withdrawn NCT04702048 - Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye Phase 4
Completed NCT03345667 - Assessment of Color Vision in Diabetic Patients N/A
Recruiting NCT05746975 - Diabetic Retinopathy Classification: ETDRS 7-fields vs Widefield Imaging (ClarusDR)